<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2306210821
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AVODART 0.5MG CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DUTASTERIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        111.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DELPHARM POZNAN SPOLKA AKCYJNA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DELPHARM POZNAN SPOLKA AKCYJNA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1182]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04CB02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><em>AVODART</em> is used to treat men with an enlarged prostate </strong><em>(benign prostatic hyperplasia) </em><strong>-</strong> a non-cancerous growth of the prostate gland caused by producing too much of a hormone called DHT (<em>dihydrotestosterone</em>). The active ingredient is dutasteride. It belongs to a group of medicines called 5-alpha reductase inhibitors.</p><p>As the prostate grows, it can lead to urinary problems, such as difficulty in passing urine and a need to go to the toilet more frequently. It can also cause the flow of the urine to be slower and less forceful. If left untreated, there is a risk that your urine flow will be completely blocked. <em>AVODART</em> or <em>AVODART</em> in combination with another type of medicine called an alpha-blocker helps to shrink the prostate and relieve symptoms, by reducing the amount of DHT your body produces.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Don&rsquo;t take/use <em>AVODART</em></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if <strong>you&rsquo;re allergic <em>(hypersensitive)</em> to dutasteride</strong> or to any of the other ingredients of <em>AVODART</em> (listed in Section 6), or to other medicines known as 5-alpha reductase inhibitors</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are <strong>female </strong>or<strong> under 18 years of age</strong>.&nbsp; This medicine is for <strong>adult men only</strong>.</p><p><!--[if !supportLists]-->&egrave; <!--[endif]-->If any of these apply to you,<strong> don&rsquo;t take <em>AVODART</em></strong> until you have checked with your doctor</p><p>Take special care with <em>AVODART</em></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->In clinical studies with <em>AVODART</em>, some patients took <em>AVODART</em> and a type of medicine called an alpha-blocker (for example tamsulosin). The patients taking <strong><em>AVODART</em> and an alpha-blocker</strong> had heart failure more often than patients taking only <em>AVODART</em>or only an alpha-blocker. (Heart failure means your heart does not pump blood as well as it should.)</p><p><!--[if !supportLists]-->&egrave; <!--[endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking <em>AVODART</em>and an alpha-blocker, <strong>talk to your doctor</strong> about this and other possible side effects</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>If you have liver disease</strong>, check with your doctor that <em>AVODART</em> is suitable for you. You may need extra check-ups while you are taking <em>AVODART</em>.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Women, children and adolescents must not handle leaking <em>AVODART</em> capsules, because the active ingredient can be absorbed through the skin. <strong>Wash the affected area immediately</strong> with soap and water if there is any contact with the skin</p><p><!--[if !supportLists]-->&egrave; <!--[endif]--><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Contact your doctor or pharmacist</strong> if you have any questions about taking <em>AVODART</em></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>AVODART</em> may cause breast enlargement and tenderness.&nbsp; If this becomes troublesome, or if you notice breast lumps or nipple discharge you should <strong>talk to your doctor</strong> about these changes as these may be signs of a serious condition, such as breast cancer</p><p>While you are taking <em>AVODART</em></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->In a clinical study of men at increased risk of prostate cancer, men taking <em>AVODART</em> had a <strong>serious form of prostate cancer more often</strong> than men who did not take <em>AVODART</em></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->A blood test to measure the amount of a substance called PSA (<em>prostate specific antigen</em>) in your blood can help your doctor to tell if you have prostate disease, including prostate cancer. If you have a higher than normal amount of PSA in your blood it could mean that you are at a higher risk of prostate cancer</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Men taking <em>AVODART</em> should have their PSA measured 6 months after starting treatment and regularly thereafter</strong>. Taking <em>AVODART</em> will reduce the amount of PSA measured in your blood. You could still be at risk for prostate cancer even though your PSA is lower. Your doctor can still use PSA to help detect prostate cancer, by comparing your test results each time you have a PSA test</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->It is important to take your medicine as your doctor recommends. If you do not take it regularly it may interfere with your doctor&rsquo;s ability to monitor your PSA</p><p>Other medicines and <em>AVODART</em></p><p><strong>Tell your doctor if you&rsquo;re taking any other medicines or</strong> have recently taken any. This includes medicines bought without a prescription.</p><p>Pregnancy and breast-feeding</p><p><strong>Women who are pregnant (or may be) must not handle leaking capsules</strong>. Dutasteride is absorbed through the skin and can affect the normal development of a male baby. This is a particular risk in the first 16 weeks of pregnancy.</p><p><!--[if !supportLists]-->&egrave; <!--[endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Contact your doctor</strong> for advice if a pregnant woman has come into contact with the contents of a <em>AVODART</em> capsule.</p><p><strong>Male Fertility</strong></p><p><strong><em>AVODART</em></strong><strong> has been shown to reduce sperm count,</strong> semen volume and sperm movement. However, it is not clear if male fertility is affected by <em>AVODART</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take <em>AVODART</em> exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>How much to take</p><p>The usual dose is one capsule (0.5 mg) taken once a day.</p><p>How to take</p><p><strong>Swallow your <em>AVODART</em> capsules whole with some water.&nbsp; Do not chew or open the capsules</strong>. Contact with the contents of the capsules may make your mouth or throat sore.</p><p><em>AVODART</em> is a long term treatment. Some men notice an early improvement in their symptoms. However, others may need to continue treatment for up to 6 months to see if <em>AVODART</em> helps them.</p><p>If you forget to take <em>AVODART</em></p><p><strong>Don&rsquo;t take extra capsules to make up for a missed dose</strong>. Just take your next dose at the usual time.</p><p>If you take too much <em>AVODART</em></p><p>If you take too many <em>AVODART</em> capsules, <strong>contact your doctor or pharmacist for advice</strong>. If possible, show them the <em>AVODART</em> pack.</p><p><strong>&nbsp;</strong></p><p><strong>Don&rsquo;t stop <em>AVODART</em> without advice</strong></p><p>Take <em>AVODART</em> for as long as your doctor recommends. Don&rsquo;t stop taking <em>AVODART</em> without talking to your doctor first. It may take up to 6 months or more for you to notice an effect.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, <em>AVODART</em> can cause side effects, but not everybody gets them.</p><p>Conditions you need to look out for</p><p><strong>Allergic reaction: </strong>These<strong><em> </em></strong>may affect <strong>up to 1 in 10,000</strong> people. Signs can include:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->raised and itchy rash (<em>hives</em>)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->swelling, sometimes of the face or mouth (<em>angioedema</em>) causing difficulty in breathing</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->collapse</p><p><!--[if !supportLists]-->&egrave; <!--[endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Contact a doctor immediately </strong>if you get any of these symptoms. <strong>Stop taking <em>AVODART</em></strong></p><p>Common side effects</p><p>These may affect <strong>up to 1 in 10</strong> people:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->not able to achieve or maintain an erection (impotence)<sup>*</sup></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->decreased sex drive (libido)<sup> *</sup></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->difficulty with ejaculation<sup>*</sup></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->breast enlargement or tenderness (gynecomastia)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->dizziness when taken with tamsulosin</p><p><sup>*</sup> In a small number of people some of these events may continue after you stop taking <em>AVODART</em></p><p><strong>Rare side effects</strong></p><p>These may affect up to 1 in 1,000 people:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->hair loss (usually from the body) or hair growth</p><p>Very rare side effects</p><p>These may affect up to 1 in 10,000 people:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->allergic reactions</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->depressed mood</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->pain and swelling in your testicles</p><p>If you get side effects</p><p><!--[if !supportLists]-->&egrave; <!--[endif]--><strong>Tell your doctor or pharmacist</strong> if any of the side effects listed becomes <strong>severe or troublesome</strong>, or if you notice any side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Keep out of the reach and sight of children.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not use <em>AVODART</em> after the expiry date which is stated on the pack after &lsquo;Exp&rsquo;.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->store <em>AVODART</em> below 30&deg;C.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If your doctor tells you to stop taking <em>AVODART</em>, it is important to return any remnants which are left over to your pharmacist.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What <em>AVODART</em> contains</p><p><strong>The active substance is dutasteride</strong>.<strong> </strong>Each capsule contains 0.5 mg dutasteride.</p><p><em>The other ingredients are:</em></p><p>Capsule contents: monodiglycerides of caprylic/capric acid; butylated hydroxytoluene</p><p>Capsule shell: gelatin; glycerol; titanium dioxide (E171, CI 77891); iron oxide yellow (E172, CI 77492).</p><p>Medium chain triglycerides and lecithin as capsule lubricants.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What AVODART looks like and contents of the pack
AVODART capsules are oblong opaque, dull-yellow, soft gelatin capsules,
marked with GX CE2. PVC/PVDC blisters.
Not all packs are available in every country.

AVODART is a trademark owned by or licenced to GSK group of companies.
© 2019 GSK, all rights reserved.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by:</strong></p><p>GlaxoSmithKline Pharmaceutical S.A.*, Poznan, Poland</p><p><strong>Packed by:</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA<strong> </strong></p><p><strong>Marketing Authorisation Holder</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia</p><p>*member of the GlaxoSmithKline group of companies</p><p><strong>For any information about this medicinal product, please contact: </strong></p><p><strong>-GlaxoSmithKline - Head Office, Jeddah </strong></p><p>&bull; Tel: +966-12-6536666</p><p>&bull; Mobile: +966-56-904-9882</p><p>&bull; Email: sa.aermi-saudi@gsk.com</p><p>&bull; website: https://healthksa.gsk.com/</p><p>&bull; P.O. Box 55850, Jeddah 21544, Saudi Arabia.</p><table cellspacing="1" cellpadding="1" border="1" style="width:500px"><tbody><tr><td><p><strong>To report any side effect(s): </strong></p><p><strong><em>Kingdom of Saudi Arabia </em></strong></p><p><strong>-National Pharmacovigilance centre (NPC) </strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Fax: +966-11-205-7662</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Call NPC at +966-11-2038222, Ext: 2317-2356-2340</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Reporting hotline: 19999</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->E-mail: npc.drug@sfda.gov.sa</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p><strong>-GlaxoSmithKline - Head Office, Jeddah </strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Tel: +966-12-6536666</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Mobile: +966-56-904-9882</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Email: sa.aermi-saudi@gsk.com</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->website: https://healthksa.gsk.com/</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->P.O. Box 55850, Jeddah 21544, Saudi Arabia</p></td></tr></tbody></table><p>&nbsp;</p><table cellspacing="1" cellpadding="1" border="1" style="width:500px"><tbody><tr><td><p><strong>THIS IS A MEDICAMENT</strong></p><p>- Medicament is a product which affects your health, and its consumption contrary to instructions is dangerous for you.</p><p>- Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p>- The doctor and the pharmacist are experts in medicine, its benefits and risks.</p><p>- Do not by yourself interrupt the period of treatment prescribed for you.</p><p>- Do not repeat the same prescription without consulting your doctor.</p><p>- Keep all medicine out of reach of children</p><p>Council of Arab Health Ministers</p><p>Union of Arab Pharmacists</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                GDS Version Number: GDS20
Date of issue: 11 April 2016

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>يُستخدم دواء<em> </em>أڤودارت في علاج الرجال المصابين بتضخم البروستاتة</strong> <em>(فرط التنسج البروستاتي الحميد)</em><strong><em> </em></strong>- وهو عبارة عن ورم غير سرطاني في غدة البروستاتة ينتج عن زيادة إفراز هرمون</p><p>(DHT)</p><p>(<em>دايهيدروتستوستيرون</em>). المادة الفعالة بهذا الدواء هي دوتاستيرايد. وهي تنتمي إلى مجموعة من الأدوية تُسمى مثبطات مختزلة الألفا-5.</p><p>قد تؤدي زيادة حجم البروستاتة إلى حدوث مشكلات في الجهاز البولي مثل صعوبة التبول والحاجة إلى التبول بصورة متكررة. كما قد تؤدي إلي إبطاء سرعة تدفق البول وقوته. وإذا لم تتم معالجة تضخم البروستاتة فستكون هناك خطورة حدوث انسداد في مجرى البول. يساعد أڤودارت أو أڤودارت بالإضافة إلى نوع آخر من الأدوية يُسمى حاصر مستقبلات ألفا على تقليل حجم البروستاتة والتخفيف من الأعراض عن طريق التقليل من كميات هرمون الدايهيدروتستوستيرون التي ينتجها جسدك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تجنب تناول/استعمال أڤودارت</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا <strong>كانت لديك حساسية</strong> <strong><em>(فرط التحسس)</em></strong> <strong>من الدوتاستيرايد</strong> أو أي من المواد الأخرى المستخدمة في أڤودارت (المدرجة في فقرة 6)، أو أي من الأدوية الأخرى التي تُسمى مثبطات مختزلة الألفا-5</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنتِ <strong>سيدة</strong> أو <strong>يقل عمرك عن 18 عامًا</strong>. هذا الدواء مخصص <strong>للرجال البالغين فقط</strong></p><p>&ccedil;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت أي من هذه الحالات تنطبق عليك،<strong> فلا تتناول أڤودارت</strong> إلا بعد استشارة الطبيب.</p><p>توخ الحذر عند تناول أڤودارت</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في دراسات إكلينيكية أجريت على أڤودارت، تناول بعض المرضى أڤودارت مع دواء آخر يُسمى حاصر مستقبلات ألفا (تامسولوسين، على سبيل المثال). ووجدت الدراسات أن المرضى الذين كانوا يتناولون <strong>أڤودارت وحاصر مستقبلات ألفا معًا</strong> تعرضوا للإصابة بقصور في القلب بنسبة أكبر من المرضى الذين تناولوا أڤودارت أو حاصر مستقبلات ألفا فقط. (قصور القلب يعني أن قلبك لا يقوم بضخ الدم كما ينبغي.)</p><p>&ccedil;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أڤودارت وحاصر مستقبلات ألفا معًا، <strong>تحدث إلى طبيبك</strong> بشأن هذا والآثار الجانبية المحتملة الأخرى</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>إذا كنت مصابًا بمرض في الكبد</strong>، استشر طبيبك لمعرفة إذا ما كان أڤودارت مناسبًا لك.<br />فقد تحتاج إلى إجراء المزيد من الفحوصات أثناء تناولك لدواء أڤودارت.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يجب على النساء والأطفال والمراهقين عدم لمس كبسولات أڤودارت التي يتسرب منها الدواء، حيث أن المادة الفعالة يمكن امتصاصها من خلال الجلد.<strong> قم بغسل المنطقة المتأثرة على الفور </strong>بالماء والصابون في حالة ملامسة المادة الفعالة للجلد</p><p>&ccedil;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اتصل بالطبيب أو الصيدلاني </strong>إذا كانت لديك أي استفسارات بشأن تناول أڤودارت</p><p><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]-->قد يتسبب أڤودارت في تضخم الثديين والشعور بألم فيهما. إذا تسبب لك ذلك في انزعاج، أو إذا لاحظت تكون كتل في الثديين أو خروج إفرازات من الحلمة فيجب عليك <strong>التحدث مع طبيبك</strong> بشأن هذه التغيرات حيث قد تكون علامات على الإصابة بحالة أكثر خطورة، مثل سرطان الثدي</p><p>أثناء تناول أڤودارت</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في إحدى الدراسات الإكلينيكية التي تناولت الرجال الأكثر عرضة للإصابة بسرطان البروستاتة، وجد أن الرجال الذين يتناولون أڤودارت <strong>يتعرضون لحالة خطرة من سرطان البروستاتة بدرجة أكبر</strong> من الرجال الذين لم يتناولوا أڤودارت</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن اختبار الدم الذي يقيس كمية مادة تُسمى PSA (<em>المستضد البروستاتي النوعي</em>) في دمك يساعد الطبيب على معرفة ما إذا كنت مصابًا بمرض في البروستاتة، بما في ذلك سرطان البروستاتة. فإذا كان لديك كمية تزيد عن المستوى الطبيعي من المستضد البروستاتي النوعي في دمك فذلك يعني أنك أكثر عرضة للإصابة بسرطان البروستاتة</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>ينبغي على الرجال الذين يتناولون أڤودارت إجراء اختبار دم لقياس مستوى المستضد البروستاتي النوعي في الدم بعد 6 أشهر من بدء العلاج، وبصورة منتظمة بعد ذلك</strong>. سيقلل تناول أڤودارت من كمية المستضد البروستاتي النوعي التي يتم قياسها في دمك. ولكنك قد لا تزال في خطر الإصابة بسرطان البروستاتة على الرغم من انخفاض مستوى المستضد البروستاتي النوعي لديك. مع ذلك، يمكن للطبيب استخدام نسبة المستضد البروستاتي النوعي للمساعدة على اكتشاف سرطان البروستاتة، عن طريق مقارنة نتائج اختباراتك في كل مرة تجري فيها اختبار المستضد البروستاتي النوعي</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->من المهم تناول الدواء حسب إرشادات الطبيب. فإذا لم تتناوله بانتظام فقد يؤثر ذلك على قدرة الطبيب على مراقبة مستويات المستضد البروستاتي النوعي لديك</p><p>تناول الدوائية الأخرى مع أڤودارت</p><p><strong>أخبر الطبيب أو الصيدلاني إذا كنت تتناول أدوية أخرى </strong>أو تناولت بعض الأدوية مؤخرًا. ويشمل هذا الأدوية التي تُشترى دون وصفة طبية.</p><p>الحمل والرضاعة</p><p><strong>يجب على النساء الحوامل (أو هناك شك بأنهن حوامل) عدم ملامسة الكبسولات التي بها تسريب</strong>. حيث يمكن أن يؤثر الدوتاستيرايد الذي يتم امتصاصه عن طريق الجلد على النمو الطبيعي للأجنة من الذكور. وتزيد هذه الخطورة خلال أول 16 أسبوعًا من الحمل.</p><p>&ccedil;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>استشر الطبيب</strong> في حالة لمس سيدة حامل لمحتوى كبسولة أڤودارت.</p><p><strong>الخصوبة عند الرجال</strong></p><p><strong>لقد وجد<em> </em>أن<em> </em>أڤودارت يقلل من عدد الحيوانات المنوية</strong> وكمية السائل المنوي وحركة الحيوانات المنوية. ومع ذلك، ليس من الواضح ما إذا كانت الخصوبة عند الرجال تتأثر سلبًا بدواء أڤودارت أم لا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول أڤودارت حسب إرشادات الطبيب دائمًا. يجب عليك مراجعة الطبيب أو الصيدلاني إذا لم تكن واثقًا من هذا الشأن.</p><p>الجرعة الواجب تناولها</p><p>الجرعة المعتادة هي كبسولة واحدة (0<strong>.</strong>5 ملجم) تؤخذ مرة في اليوم.</p><p>طريقة تناول الجرعة</p><p><strong>ابتلع كبسولة أڤودارت كاملة مع بعض الماء. لا تقم بمضغ الكبسولة أو فتحها</strong>. قد تؤدي ملامسة محتويات الكبسولة إلى التهاب الفم والحلق.</p><p>إن أڤودارت هو علاج يستمر على المدى الطويل. يلاحظ بعض الرجال تحسن مبكر في الأعراض. ولكن قد يحتاج البعض الآخر إلى الاستمرار في تناول الدواء حتى 6 أشهر لمعرفة ما إذا كان أڤودارت سوف يساعدهم.</p><p>في حال نسيان تناول جرعة أڤودارت</p><p><strong>لا تتناول كبسولات إضافية لتعويض الجرعة التي فاتتك</strong>. فقط تناول الجرعة التالية في الموعد المعتاد.</p><p>في حال تناول جرعة زائدة من أڤودارت</p><p>إذا تناولت عددًا كبيرًا من كبسولات أڤودارت،<strong> استشر الطبيب أو الصيدلاني بهذا الشأن</strong>. ويُفضل أن تريهم عبوة أڤودارت إن أمكن.</p><p>لا تتوقف عن تناول أڤودارت دون مشورة</p><p>تناول أڤودارت طوال المدة التي أوصى بها طبيبك. لا تتوقف عن تناول أڤودارت دون استشارة الطبيب أولاً. فقد يستغرق الأمر حتى 6 أشهر أو أكثر لتلاحظ أي تأثير للدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو حال جميع الأدوية، يمكن أن يتسبب أڤودارت في حدوث بعض الأعراض الجانبية، لكن ليس بالضرورة أن يصاب جميع الأشخاص بهذه الأعراض.</p><p>حالات ينبغي الانتباه لها</p><p><strong>تفاعل الحساسية:</strong> قد تصيب <strong>حتى</strong> <strong>واحد من بين كل 10000</strong> شخص. وتشمل أعراض الحساسية:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->طفح جلدي بارز ويسبب حكة (<em>الشرى</em>)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->حدوث تورم في بعض الأحيان للوجه والفم (<em>وذمة وعائية</em>) مما ينتج عنه صعوبة في التنفس</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->انهيار</p><p>&ccedil;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اتصل بالطبيب على الفور</strong> إذا أصبت بأي من هذه الأعراض. <strong>توقف عن تناول أڤودارت</strong></p><p>الأعراض الجانبية الشائعة</p><p>قد تصيب <strong>حتى</strong> <strong>واحد من بين كل 10</strong> أشخاص:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->عدم القدرة على الانتصاب أو استمراره (الضعف الجنسي)<sup>*</sup></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->نقص الرغبة الجنسية<sup> *</sup></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مواجهة صعوبة في القذف<sup>*</sup></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تضخم الثديين أو الشعور بألم فيهما (تثدي الرجل)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->دوار عند تناوله مع تامسولوسين</p><p><sup>*</sup> قد تستمر بعض هذه الأعراض لدى عدد قليل من الأشخاص بعد التوقف عن تناول أڤودارت.</p><p><strong>&nbsp;</strong></p><p>الأعراض الجانبية النادرة</p><p>قد تصيب حتى واحد من بين كل 1000 شخص:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->سقوط الشعر (عادة من الجسم) أو زيادة نموه</p><p>&nbsp;</p><p>الأعراض الجانبية شديدة الندرة</p><p>قد تصيب حتى واحد من بين كل 10.000 شخص:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الحساسية</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->حالة اكتئاب</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم وتورم في الخصيتين</p><p>في حالة الإصابة بالأعراض الجانبية</p><p><!--[if !supportLists]-->&ccedil;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>أخبر الطبيب أو الصيدلاني</strong> في حالة <strong>تفاقم</strong> أي من الأعراض الجانبية الموضحة هنا أو كانت مزعجة، أو إذا لاحظت أعراضًا جانبية أخرى غير مدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>يُحفظ بعيدًا عن متناول ومرأى الأطفال.</li><li>لا تستخدم أڤودارت بعد انتهاء تاريخ الصلاحية المدون على العبوة بعد &quot;Exp&quot;.</li></ul><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا طلب منك طبيبك التوقف عن تناول أڤودارت، فمن المهم إرجاع باقي العقار إلى الصيدلي.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تجنب التخلص من الأدوية عبر مياه الصرف أو فضلات المنزل. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. سوف تساعدك هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما هي مكونات أڤودارت</p><p><strong>المادة الفعالة بهذا الدواء هي دوتاستيرايد</strong>. تحتوي كل كبسولة على 0.5 ملجم من الدوتاستيرايد.<strong> </strong></p><p><em>أما المكونات الأخرى فهي:</em></p><p>محتويات الكبسولة: منوندايجليسريد حمض الكاپريليك/الكاپريك، بوتيل هيدروكسي تولوين</p><p>غلاف الكبسولة: جيلاتين، جليسرول، ثاني أكسيد التيتانيوم (E171، CI 77891)، أكسيد الحديد الأصفر (E172، CI 77492).</p><p>تُستخدم الجليسريدات الثلاثية متوسطة الحلقات والليسيثين كمزلقات للكبسولات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>إن كبسولات أڤودارت هي كبسولات جيلاتينية لينة مستطيلة وغير شفافة ذات لون أصفر باهت، وتحمل رمز GX CE2. الشرائط البلاستيكية مصنوعة من كلوريد البولي فينيل/كلوريد البولي فينيلدين. لا تسوق جميع أحجام العبوات في كل بلد. أڤودارت علامة تجارية مملوكة أو مرخصة لمجموعة شركات جلاكسو سميث كلاين. &copy;2019 مجموعة شركات جلاكسو سميث كلاين. جميع الحقوق محفوظة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>تصنيع:</strong></p><p>جلاكسو سميث كلاين فارماسيتيكالز إس.أيه.* بوزنان، بولندا</p><p><strong>تعبئة:</strong></p><p>جلاكسو العربية السعودية المحدودة*، جدة، السعودية</p><p><strong>الشركة المالكة لرخصة التسويق</strong></p><p>جلاكسو العربية السعودية المحدودة*، جدة، السعودية</p><p>العنوان: صندوق بريد22617، جدة 21416، المملكة العربية السعودية</p><p>*عضو في مجموعة شركات جلاكسو سميث كلاين</p><p><strong>للاستفسار عن أية معلومات عن هذا المستحضر الدوائي، يرجى الاتصال بالأرقام التالية:</strong></p><p>جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</p><p>هاتف: 6536666 (12) 966 +</p><p>المحمول : 9882-904-56 &nbsp;966 +</p><p>البريد اللكتروني : sa.aermi-saudi@gsk.com</p><p>الموقع الإلكتروني : https://healthksa.gsk.com/</p><p>ص.ب 55850، جدة 21544، المملكة العربية السعودية</p><table cellspacing="1" cellpadding="1" border="1" style="width:500px"><tbody><tr><td><p><strong>للإبلاغ عن أية آثار جانبية:</strong></p><p><strong><em>المملكة العربية السعودية</em></strong></p><p><strong>- المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فاكس: 7662-205-11-966 +</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية. هاتف:2038222-11-966+ تحويلة:2340-2356-2317</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الخط الساخن:19999</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الموقع الإلكتروني: www.sfda.gov.sa/npc</p><p><strong>- جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->هاتف: 6536666 (12) 966 +</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المحمول : 9882-904-56 &nbsp;966 +</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->البريد اللكتروني : sa.aermi-saudi@gsk.com</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الموقع الإلكتروني: https://healthksa.gsk.com/</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ص.ب 55850، جدة 21544، المملكة العربية السعودية.</p></td></tr></tbody></table><table cellspacing="1" cellpadding="1" border="1" style="width:500px"><tbody><tr><td><p><strong>إن هذا الدواء</strong></p><p>- الدواء مستحضر يؤثر على صحتك، واستهلاكه خلافا للتعليمات يعرضك للخطر.</p><p>- اتبع بدقة وصفة الطبيب، وطريقة الاستعمال المنصوص عليها، وتعليمات الصيدلانى الذى صرفها لك.</p><p>- فالطبيب و الصيدلانى هما الخبيران بالدواء، وبنفعه و ضرره.</p><p>- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p>- لا تكرر صرف الدواء بدون استشارة الطبيب.</p><p>- احتفظ بجميع الأدوية بعيداً عن متناول لأطفال.&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مجلس وزراء الصحة العرب</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; اتحاد الصيادلة العرب</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	رقم الإصدار: GDS20
	تاريخ الإصدار: 11 أبريل 2016

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AVODART
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule for oral use contains 0.5 mg dutasteride (see List of Excipients). 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsules: dull yellow in colour, opaque, oblong soft gelatin capsules marked with GX CE2.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>AVODART</em> treats and prevents progression of benign prostatic hyperplasia (BPH) through alleviating symptoms, reducing prostate size (volume), improving urinary flow rate and reducing the risk of acute urinary retention (AUR) and the need for BPH‑related surgery.</p><p><em>AVODART</em> in combination with the alpha‑blocker tamsulosin, treats and prevents progression of benign prostatic hyperplasia (BPH) by reducing prostate size, alleviating symptoms, improving urinary flow and reducing the risk of acute urinary retention (AUR) and the need for BPH‑related surgery (<em>see Clinical Studies</em>).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adult males (including elderly)</p><p>Capsules should be swallowed whole and not chewed or opened, as contact with the capsule contents may result in irritation of the oropharyngeal mucosa.</p><p><em>AVODART</em> may be taken with or without food.</p><p>The recommended dose of <em>AVODART </em>is one capsule (0.5 mg) taken orally once a day.</p><p>Although an improvement may be observed at an early stage, treatment for at least 6&nbsp;months may be necessary in order to assess objectively whether a satisfactory response to the treatment can be achieved.</p><p>For treatment of BPH, <em>AVODART </em>can be administered alone or in combination with the alpha-blocker tamsulosin (0.4&nbsp;mg).</p><p>Renal impairment</p><p>The effect of renal impairment on dutasteride pharmacokinetics has not been studied. However, no adjustment in dosage is anticipated for patients with renal impairment (<em>see Pharmacokinetics</em>).</p><p>Hepatic impairment</p><p>The effect of hepatic impairment on dutasteride pharmacokinetics has not been studied (<em>see Warnings</em><em> and Precautions and Pharmacokinetics</em>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AVODART is contraindicated in patients with known hypersensitivity to dutasteride, other 5 alpha reductase inhibitors, or any component of the preparation (see List of Excipients).
AVODART is contraindicated for use in women and children (see Pregnancy and Lactation).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Prostate cancer</strong></p><p>In a 4-year study of over 8,000 men aged 50 to 75, with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 ng/mL and 10.0 ng/mL (the REDUCE study), 1,517 men were diagnosed with prostate cancer.&nbsp; There was a higher incidence of Gleason 8-10 prostate cancers in the <em>AVODART</em> group (n=29, 0.9%) compared to the placebo group (n=19, 0.6%).&nbsp; There was no increased incidence in Gleason 5-6 or 7-10 prostate cancers. No causal relationship between <em>AVODART</em> and high grade prostate cancer has been established.&nbsp; The clinical significance of the numerical imbalance is unknown.&nbsp; Men taking <em>AVODART</em> should be regularly evaluated for prostate cancer risk including PSA testing.</p><p>In an additional 2-year follow-up study with the original patients from the dutasteride chemoprevention study (REDUCE), a low rate of new prostate cancers were diagnosed (dutasteride [n=14, 1.2%] and placebo [n=7, 0.7%]), with no new identified cases of Gleason 8&ndash;10 prostate cancers.</p><p>Long-term follow up (up to 18 years) of another 5-ARI (finasteride) in a chemoprevention study showed no statistically significant difference between finasteride and placebo in the rates of overall survival (HR 1.02, 95% CI 0.97-1.08) or survival after prostate cancer diagnoses (HR 1.01, 95% CI 0.85-1.20).</p><p><strong>Prostate specific antigen (PSA)</strong></p><p>Serum prostate-specific antigen (PSA) concentration is an important component of the screening process to detect prostate cancer.&nbsp; <em>AVODART</em> causes a decrease in mean serum PSA levels by approximately 50% after 6&nbsp;months of treatment.</p><p>Patients receiving <em>AVODART</em> should have a new PSA baseline established after 6 months of treatment with <em>AVODART</em>. It is recommended to monitor PSA values regularly thereafter. Any confirmed increase from lowest PSA level while on <em>AVODART</em> may signal the presence of prostate cancer or non-compliance to therapy with <em>AVODART</em> and should be carefully evaluated, even if those values are still within the normal range for men not taking a 5-ARI<em>.</em> In the interpretation of a PSA value for a patient taking <em>AVODART</em>, previous PSA values should be sought for comparison.</p><p>Treatment with <em>AVODART</em> does not interfere with the use of PSA as a tool to assist in the diagnosis of prostate cancer after a new baseline has been established.</p><p>Total serum PSA levels return to baseline within 6 months of discontinuing treatment.</p><p>The ratio of free to total PSA remains constant even under the influence of <em>AVODART. </em>If clinicians elect to use percent‑free PSA as an aid in the detection of prostate cancer in men undergoing <em>AVODART </em>therapy, no adjustment to its value is necessary.</p><p>Digital rectal examination, as well as other evaluations for prostate cancer, should be performed on patients prior to initiating therapy with <em>AVODART</em> and periodically thereafter.</p><p><strong>Cardiovascular adverse events</strong></p><p>In two 4-year clinical studies, the incidence of cardiac failure (a composite term of reported events, primarily cardiac failure and congestive cardiac failure) was higher among subjects taking the combination of <em>AVODART</em> and an alpha blocker, primarily tamsulosin, than it was among subjects not taking the combination.&nbsp; In these two trials, the incidence of cardiac failure was low (&le;1%) and variable between the studies.&nbsp; No imbalance was observed in the incidence of cardiovascular adverse events overall in either trial.&nbsp; No causal relationship between <em>AVODART</em> (alone or in combination with an alpha blocker) and cardiac failure has been established (<em>see Clinical Studies</em>).</p><p>In a meta-analysis of 12-randomised, placebo- or comparator-controlled clinical studies (n=18,802) that evaluated the risks of developing cardiovascular adverse events from the use of <em>AVODART</em> (by comparison with controls), no consistent statistically significant increase in the risk of heart failure (RR 1.05; 95% CI 0.71, 1.57), acute myocardial infarction (RR 1.00; 95% CI 0.77, 1.30) or stroke (RR 1.20; 95% CI 0.88, 1.64) were found.</p><p><strong>Breast cancer</strong></p><p>There have been rare reports of male breast cancer reported in men taking AVODART in clinical trials and during the post-marketing period.&nbsp; However, epidemiological studies showed no increase in the risk of developing male breast cancer with the use of 5‑ARIs (see Clinical Studies). Prescribers should instruct their patients to promptly report any changes in their breast tissue such as lumps or nipple discharge.</p><p><strong>Leaking capsules</strong></p><p>Dutasteride is absorbed through the skin, therefore women and children must avoid contact with leaking capsules (<em>see Pregnancy and Lactation</em>). If contact is made with leaking capsules the contact area should be washed immediately with soap and water.</p><p><strong>Hepatic impairment</strong></p><p>The effect of hepatic impairment on dutasteride pharmacokinetics has not been studied. Because dutasteride is extensively metabolised and has a half-life of 3 to 5 weeks, caution should be used in the administration of dutasteride to patients with liver disease (<em>see Dosage</em><em> and Administration and Pharmacokinetics</em>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In vitro</em> drug metabolism studies show that dutasteride is metabolised by human cytochrome P450 isoenzyme CYP3A4. Therefore blood concentrations of dutasteride may increase in the presence of inhibitors of CYP3A4.</p><p>Phase II data showed a decrease in clearance of dutasteride when co-administered with the CYP3A4 inhibitors verapamil (37%) and diltiazem (44%).&nbsp; In contrast no decrease in clearance was seen when amlodipine, another calcium channel antagonist, was co‑administered with dutasteride. A decrease in clearance and subsequent increase in exposure to dutasteride, in the presence of CYP3A4 inhibitors, is unlikely to be clinically significant due to the wide margin of safety (up to 10‑times the recommended dose has been given to patients for up to six months), therefore no dose adjustment is necessary.</p><p><em>In vitro</em>, dutasteride is not metabolised by human cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2E1, CYP2C8, CYP2C9, CYP2C19, CYP2B6 and CYP2D6.</p><p>Dutasteride neither inhibits human cytochrome P450 drug-metabolizing enzymes in vitro nor induces cytochrome P450 isoenzymes CYP1A, CYP2B, and CYP3A in rats and dogs in vivo.&nbsp;</p><p>In vitro studies demonstrate that dutasteride does not displace warfarin, diazepam, acenocoumorol, phenprocoumon, or phenytoin from plasma protein, nor do these model compounds displace dutasteride.&nbsp; Compounds that have been tested for drug interactions in man include tamsulosin, terazosin, warfarin, digoxin, and cholestyramine, and no clinically significant pharmacokinetic or pharmacodynamic interactions have been observed.</p><p>Although specific interaction studies were not performed with other compounds, approximately 90% of the subjects in large Phase III studies receiving dutasteride were taking other medications concomitantly. No clinically significant adverse interactions were observed in clinical trials when dutasteride was co‑administered with anti‑hyperlipidemics, angiotensin‑converting enzyme (ACE) inhibitors, beta‑adrenergic blocking agents, calcium channel blockers, corticosteroids, diuretics, nonsteroidal anti‑inflammatory drugs (NSAIDs), phosphodiesterase Type V inhibitors, and quinolone antibiotics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fertility</p><p>The effects of dutasteride 0.5 mg/day on semen characteristics were evaluated in normal volunteers aged 18 to 52 (n=27 dutasteride, n=23 placebo) throughout 52 weeks of treatment and 24 weeks of post treatment follow-up.&nbsp; At 52 weeks, the mean percent reduction from baseline in total sperm count, semen volume, and sperm motility were 23%, 26%, and 18%, respectively, in the dutasteride group when adjusted for changes from baseline in the placebo group. Sperm concentration and sperm morphology were unaffected. After 24 weeks of follow-up, the mean percent change in total sperm count in the dutasteride group remained 23% lower than baseline. While mean values for all semen parameters at all time points remained within the normal ranges and did not meet predefined criteria for a clinically significant change (30%), two subjects in the dutasteride group had decreases in sperm count of greater than 90% from baseline at 52 weeks, with partial recovery at the 24-week follow-up. The clinical significance of dutasteride&#39;s effect on semen characteristics for an individual patient&rsquo;s fertility is not known.</p><p>Pregnancy</p><p>Dutasteride<em> </em>is contraindicated for use by women. Dutasteride has not been studied in women because pre‑clinical data suggests that the suppression of circulating levels of dihydrotestosterone may inhibit the development of the external genital organs in a male foetus carried by a woman exposed to dutasteride.</p><p>Lactation</p><p>It is not known whether dutasteride is excreted in breast milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on the pharmacokinetic and pharmacodynamic properties of dutasteride treatment with dutasteride would not be expected to interfere with the ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Clinical Trial Data</p><p><strong><em>AVODART</em> Monotherapy for BPH</strong><br /><strong><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></strong></p><p>The following investigator‑judged drug‑related adverse events (with incidence &sup3;1%) have been reported more commonly in the three phase III placebo controlled studies on <em>AVODART</em> treatment compared to placebo:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top; width:95.4pt"><p>Adverse event</p></td><td colspan="2" style="vertical-align:top; width:160.35pt"><p>Incidence during year 1 of treatment</p></td><td colspan="2" style="vertical-align:top; width:170.5pt"><p>Incidence during year 2 of&nbsp; treatment</p></td></tr><tr><td style="vertical-align:top; width:75.1pt"><p>Placebo</p><p>(n=&nbsp; 2158)</p></td><td style="vertical-align:top; width:85.25pt"><p><em>AVODART</em></p><p>(n= 2167 )</p></td><td style="vertical-align:top; width:85.25pt"><p>Placebo</p><p>(n= 1736 )</p></td><td style="vertical-align:top; width:85.25pt"><p><em>AVODART</em></p><p>(n= 1744)</p></td></tr><tr><td style="vertical-align:top; width:95.4pt"><p>Impotence*</p></td><td style="vertical-align:top; width:75.1pt"><p>3%</p></td><td style="vertical-align:top; width:85.25pt"><p>6%</p></td><td style="vertical-align:top; width:85.25pt"><p>1%</p></td><td style="vertical-align:top; width:85.25pt"><p>2%</p></td></tr><tr><td style="vertical-align:top; width:95.4pt"><p>Altered (decreased) libido*</p></td><td style="vertical-align:top; width:75.1pt"><p>2%</p></td><td style="vertical-align:top; width:85.25pt"><p>4%</p></td><td style="vertical-align:top; width:85.25pt"><p>&lt;1%</p></td><td style="vertical-align:top; width:85.25pt"><p>&lt;1%</p></td></tr><tr><td style="vertical-align:top; width:95.4pt"><p>Ejaculation disorders*</p></td><td style="vertical-align:top; width:75.1pt"><p>&lt;1%</p></td><td style="vertical-align:top; width:85.25pt"><p>2%</p></td><td style="vertical-align:top; width:85.25pt"><p>&lt;1%</p></td><td style="vertical-align:top; width:85.25pt"><p>&lt;1%</p></td></tr><tr><td style="vertical-align:top; width:95.4pt"><p>Breast disorders+&nbsp;</p></td><td style="vertical-align:top; width:75.1pt"><p>&lt;1%</p></td><td style="vertical-align:top; width:85.25pt"><p>1%</p></td><td style="vertical-align:top; width:85.25pt"><p>&lt;1%</p></td><td style="vertical-align:top; width:85.25pt"><p>1%</p></td></tr></tbody></table><p><sup>*</sup> These sexual adverse events are associated with dutasteride treatment (including monotherapy and combination with tamsulosin). These adverse events may persist after treatment discontinuation. The role of dutasteride in this persistence is unknown.<strong><em> </em></strong></p><p>+ includes breast tenderness and breast enlargement</p><p>No change to the adverse event profile was apparent over a further 2&nbsp;years in open‑label extension studies.</p><p><strong><em>AVODART</em></strong><strong> and Tamsulosin Combination Therapy for BPH</strong></p><p>The following investigator-judged drug-related adverse events (with a cumulative incidence of greater than or equal to 1%) have been reported in the CombAT (Combination of <em>AVODART</em> and Tamsulosin) Study, a comparison of <em>AVODART</em> 0.5&nbsp;mg and tamsulosin 0.4mg once daily for four years in combination or as monotherapy.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="height:17.55pt; vertical-align:bottom; width:141.75pt"><p>Adverse Reaction</p></td><td colspan="4" style="height:17.55pt; vertical-align:top; width:295.8pt"><p>Incidence during treatment period</p></td></tr><tr><td style="height:19.4pt; width:78.0pt"><p>Year&nbsp;1</p></td><td style="height:19.4pt; width:77.95pt"><p>Year&nbsp;2</p></td><td style="height:19.4pt; width:75.25pt"><p>Year&nbsp;3</p></td><td style="height:19.4pt; width:64.6pt"><p>Year&nbsp;4</p></td></tr><tr><td style="height:14.8pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Combination<sup>a </sup>(n)</p></td><td style="height:14.8pt; vertical-align:top; width:78.0pt"><p>(n=1610)</p></td><td style="height:14.8pt; vertical-align:top; width:77.95pt"><p>(n=1428)</p></td><td style="height:14.8pt; vertical-align:top; width:75.25pt"><p>(n=1283)</p></td><td style="height:14.8pt; vertical-align:top; width:64.6pt"><p>(n=1200)</p></td></tr><tr><td style="height:19.9pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Dutasteride</p></td><td style="height:19.9pt; vertical-align:top; width:78.0pt"><p>(n=1623)</p></td><td style="height:19.9pt; vertical-align:top; width:77.95pt"><p>(n=1464)</p></td><td style="height:19.9pt; vertical-align:top; width:75.25pt"><p>(n=1325)</p></td><td style="height:19.9pt; vertical-align:top; width:64.6pt"><p>(n=1200)</p></td></tr><tr><td style="height:19.9pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Tamsulosin</p></td><td style="height:19.9pt; vertical-align:top; width:78.0pt"><p>(n=1611)</p></td><td style="height:19.9pt; vertical-align:top; width:77.95pt"><p>(n=1468)</p></td><td style="height:19.9pt; vertical-align:top; width:75.25pt"><p>(n=1281)</p></td><td style="height:19.9pt; vertical-align:top; width:64.6pt"><p>(n=1112)</p></td></tr><tr><td style="height:.2in; vertical-align:top; width:141.75pt"><p>Impotence<sup>b</sup></p></td><td style="height:.2in; vertical-align:top; width:78.0pt"><p>&nbsp;</p></td><td style="height:.2in; vertical-align:top; width:77.95pt"><p>&nbsp;</p></td><td style="height:.2in; vertical-align:top; width:75.25pt"><p>&nbsp;</p></td><td style="height:.2in; vertical-align:top; width:64.6pt"><p>&nbsp;</p></td></tr><tr><td style="height:15.7pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Combination<sup>a</sup></p></td><td style="height:15.7pt; vertical-align:bottom; width:78.0pt"><p>6%</p></td><td style="height:15.7pt; vertical-align:bottom; width:77.95pt"><p>2%</p></td><td style="height:15.7pt; vertical-align:bottom; width:75.25pt"><p>&lt;1%</p></td><td style="height:15.7pt; vertical-align:bottom; width:64.6pt"><p>&lt;1%</p></td></tr><tr><td style="height:15.7pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Dutasteride</p></td><td style="height:15.7pt; vertical-align:bottom; width:78.0pt"><p>5%</p></td><td style="height:15.7pt; vertical-align:bottom; width:77.95pt"><p>2%</p></td><td style="height:15.7pt; vertical-align:bottom; width:75.25pt"><p>&lt;1%</p></td><td style="height:15.7pt; vertical-align:bottom; width:64.6pt"><p>&lt;1%</p></td></tr><tr><td style="height:17.5pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Tamsulosin</p></td><td style="height:17.5pt; vertical-align:bottom; width:78.0pt"><p>3%</p></td><td style="height:17.5pt; vertical-align:bottom; width:77.95pt"><p>1%</p></td><td style="height:17.5pt; vertical-align:bottom; width:75.25pt"><p>&lt;1%</p></td><td style="height:17.5pt; vertical-align:bottom; width:64.6pt"><p>1%</p></td></tr><tr><td style="height:17.5pt; vertical-align:top; width:141.75pt"><p>Altered (decreased) libido<sup>b</sup></p></td><td style="height:17.5pt; vertical-align:bottom; width:78.0pt"><p>&nbsp;</p></td><td style="height:17.5pt; vertical-align:bottom; width:77.95pt"><p>&nbsp;</p></td><td style="height:17.5pt; vertical-align:bottom; width:75.25pt"><p>&nbsp;</p></td><td style="height:17.5pt; vertical-align:bottom; width:64.6pt"><p>&nbsp;</p></td></tr><tr><td style="height:17.5pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Combination<sup>a</sup></p></td><td style="height:17.5pt; vertical-align:bottom; width:78.0pt"><p>5%</p></td><td style="height:17.5pt; vertical-align:bottom; width:77.95pt"><p>&lt;1%</p></td><td style="height:17.5pt; vertical-align:bottom; width:75.25pt"><p>&lt;1%</p></td><td style="height:17.5pt; vertical-align:bottom; width:64.6pt"><p>0%</p></td></tr><tr><td style="height:17.5pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Dutasteride</p></td><td style="height:17.5pt; vertical-align:bottom; width:78.0pt"><p>4%</p></td><td style="height:17.5pt; vertical-align:bottom; width:77.95pt"><p>1%</p></td><td style="height:17.5pt; vertical-align:bottom; width:75.25pt"><p>&lt;1%</p></td><td style="height:17.5pt; vertical-align:bottom; width:64.6pt"><p>0%</p></td></tr><tr><td style="height:17.5pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Tamsulosin</p></td><td style="height:17.5pt; vertical-align:bottom; width:78.0pt"><p>2%</p></td><td style="height:17.5pt; vertical-align:bottom; width:77.95pt"><p>&lt;1%</p></td><td style="height:17.5pt; vertical-align:bottom; width:75.25pt"><p>&lt;1%</p></td><td style="height:17.5pt; vertical-align:bottom; width:64.6pt"><p>&lt;1%</p></td></tr><tr><td style="height:20.2pt; vertical-align:top; width:141.75pt"><p>Ejaculation disorders<sup>b</sup></p></td><td style="height:20.2pt; vertical-align:bottom; width:78.0pt"><p>&nbsp;</p></td><td style="height:20.2pt; vertical-align:bottom; width:77.95pt"><p>&nbsp;</p></td><td style="height:20.2pt; vertical-align:bottom; width:75.25pt"><p>&nbsp;</p></td><td style="height:20.2pt; vertical-align:bottom; width:64.6pt"><p>&nbsp;</p></td></tr><tr><td style="height:17.5pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Combination<sup>a</sup></p></td><td style="height:17.5pt; vertical-align:bottom; width:78.0pt"><p>9%</p></td><td style="height:17.5pt; vertical-align:bottom; width:77.95pt"><p>1%</p></td><td style="height:17.5pt; vertical-align:bottom; width:75.25pt"><p>&lt;1%</p></td><td style="height:17.5pt; vertical-align:bottom; width:64.6pt"><p>&lt;1%</p></td></tr><tr><td style="height:17.5pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Dutasteride</p></td><td style="height:17.5pt; vertical-align:bottom; width:78.0pt"><p>1%</p></td><td style="height:17.5pt; vertical-align:bottom; width:77.95pt"><p>&lt;1%</p></td><td style="height:17.5pt; vertical-align:bottom; width:75.25pt"><p>&lt;1%</p></td><td style="height:17.5pt; vertical-align:bottom; width:64.6pt"><p>&lt;1%</p></td></tr><tr><td style="height:17.5pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Tamsulosin</p></td><td style="height:17.5pt; vertical-align:bottom; width:78.0pt"><p>3%</p></td><td style="height:17.5pt; vertical-align:bottom; width:77.95pt"><p>&lt;1%</p></td><td style="height:17.5pt; vertical-align:bottom; width:75.25pt"><p>&lt;1%</p></td><td style="height:17.5pt; vertical-align:bottom; width:64.6pt"><p>&lt;1%</p></td></tr><tr><td style="height:17.5pt; vertical-align:top; width:141.75pt"><p>Breast disorders<sup>c</sup></p></td><td style="height:17.5pt; vertical-align:bottom; width:78.0pt"><p>&nbsp;</p></td><td style="height:17.5pt; vertical-align:bottom; width:77.95pt"><p>&nbsp;</p></td><td style="height:17.5pt; vertical-align:bottom; width:75.25pt"><p>&nbsp;</p></td><td style="height:17.5pt; vertical-align:bottom; width:64.6pt"><p>&nbsp;</p></td></tr><tr><td style="height:13.9pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Combination<sup>a</sup></p></td><td style="height:13.9pt; vertical-align:bottom; width:78.0pt"><p>2%</p></td><td style="height:13.9pt; vertical-align:bottom; width:77.95pt"><p>&lt;1%</p></td><td style="height:13.9pt; vertical-align:bottom; width:75.25pt"><p>&lt;1%</p></td><td style="height:13.9pt; vertical-align:bottom; width:64.6pt"><p>&lt;1%</p></td></tr><tr><td style="height:13.9pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Dutasteride</p></td><td style="height:13.9pt; vertical-align:bottom; width:78.0pt"><p>2%</p></td><td style="height:13.9pt; vertical-align:bottom; width:77.95pt"><p>1%</p></td><td style="height:13.9pt; vertical-align:bottom; width:75.25pt"><p>&lt;1%</p></td><td style="height:13.9pt; vertical-align:bottom; width:64.6pt"><p>&lt;1%</p></td></tr><tr><td style="height:15.7pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Tamsulosin</p></td><td style="height:15.7pt; vertical-align:bottom; width:78.0pt"><p>&lt;1%</p></td><td style="height:15.7pt; vertical-align:bottom; width:77.95pt"><p>&lt;1%</p></td><td style="height:15.7pt; vertical-align:bottom; width:75.25pt"><p>&lt;1%</p></td><td style="height:15.7pt; vertical-align:bottom; width:64.6pt"><p>0%</p></td></tr><tr><td style="height:18.2pt; vertical-align:top; width:141.75pt"><p>Dizziness</p></td><td style="height:18.2pt; vertical-align:bottom; width:78.0pt"><p>&nbsp;</p></td><td style="height:18.2pt; vertical-align:bottom; width:77.95pt"><p>&nbsp;</p></td><td style="height:18.2pt; vertical-align:bottom; width:75.25pt"><p>&nbsp;</p></td><td style="height:18.2pt; vertical-align:bottom; width:64.6pt"><p>&nbsp;</p></td></tr><tr><td style="height:15.7pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Combination<sup>a</sup></p></td><td style="height:15.7pt; vertical-align:bottom; width:78.0pt"><p>1%</p></td><td style="height:15.7pt; vertical-align:bottom; width:77.95pt"><p>&lt;1%</p></td><td style="height:15.7pt; vertical-align:bottom; width:75.25pt"><p>&lt;1%</p></td><td style="height:15.7pt; vertical-align:bottom; width:64.6pt"><p>&lt;1%</p></td></tr><tr><td style="height:15.7pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Dutasteride</p></td><td style="height:15.7pt; width:78.0pt"><p>&lt;1%</p></td><td style="height:15.7pt; width:77.95pt"><p>&lt;1%</p></td><td style="height:15.7pt; width:75.25pt"><p>&lt;1%</p></td><td style="height:15.7pt; width:64.6pt"><p>&lt;1%</p></td></tr><tr><td style="height:15.7pt; vertical-align:top; width:141.75pt"><p>&nbsp;&nbsp; Tamsulosin</p></td><td style="height:15.7pt; vertical-align:bottom; width:78.0pt"><p>1%</p></td><td style="height:15.7pt; vertical-align:bottom; width:77.95pt"><p>&lt;1%</p></td><td style="height:15.7pt; vertical-align:bottom; width:75.25pt"><p>&lt;1%</p></td><td style="height:15.7pt; vertical-align:bottom; width:64.6pt"><p>0%</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Combination = dutasteride 0.5&nbsp;mg once daily plus tamsulosin 0.4&nbsp;mg once daily.<br /><sup>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>These sexual adverse events are associated with dutasteride treatment (including monotherapy and combination with tamsulosin). These adverse events may persist after treatment discontinuation. The role of dutasteride in this persistence is unknown.</p><p><sup>c</sup> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes breast tenderness and breast enlargement.</p><p>&nbsp;</p><p>Postmarketing Data</p><p>&nbsp;</p><p>Adverse drug reactions are listed below by system organ class and frequency. Frequencies are defined as: very common (&sup3;1/10), common (&sup3;1/100 to &lt;1/10), uncommon (&sup3;1/1000 to &lt;1/100), rare (&sup3;1/10,000 to &lt;1/1000) and very rare (&lt;1/10,000) including isolated reports.&nbsp; Frequency categories determined from post‑marketing data refer to reporting rate rather than true frequency.</p><p>Immune system disorders<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p>Very rare:<strong><em> </em></strong>Allergic reactions, including rash, pruritus, urticaria, localised oedema, and angioedema.</p><p>Psychiatric disorders</p><p>Very rare: Depressed mood</p><p>Skin and subcutaneous tissue disorders</p><p>Rare: Alopecia (primarily body hair loss), Hypertrichosis</p><p>Reproductive system and breast disorders</p><p>&nbsp;</p><p>Very rare: Testicular pain and testicular swelling</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Fax: +966-11-205-7662</li><li>Call NPC at +966-11-208222, Ext: 2317-2356-2353-2354-2334-2340</li><li>Toll-free: 8002490000</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; 00966(012)6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: sa.aermi-saudi@gsk.com</li><li>website: https://healthksa.gsk.com/</li><li>P.O Box 55850, Jeddah 21544, Saudi Arabia.</li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In volunteer studies single doses of dutasteride up to 40 mg/day (80 times the therapeutic dose) for 7 days have been administered without significant safety concerns. In clinical studies doses of 5 mg daily have been administered to patients for 6 months with no additional adverse effects to those seen at therapeutic doses of 0.5 mg.</p><p>There is no specific antidote for dutasteride therefore, in cases of suspected overdosage, symptomatic and supportive treatment should be given as appropriate.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dutasteride is a dual inhibitor of 5&nbsp;alpha‑reductase. It inhibits both type 1 and type 2, 5 alpha‑reductase isoenzymes, which are responsible for the conversion of testosterone to dihydrotestosterone (DHT). DHT is the androgen primarily responsible for hyperplasia of glandular prostatic tissue.</p><p>Effects on DHT/Testosterone</p><p>The maximum effect of daily doses of <em>AVODART</em> on the reduction on DHT is dose<strong>‑</strong>dependent and is observed within 1 to 2 weeks.&nbsp; After 1 week and 2 weeks of daily dosing of <em>AVODART</em><strong> </strong>0.5&nbsp;mg, median serum DHT concentrations were reduced by 85% and 90%, respectively.</p><p>In BPH patients treated with 0.5 mg of dutasteride daily, the median decrease in DHT was 94% at 1 year and 93% at 2 years and the median increase in serum testosterone was 19% at both 1 and 2 years. This is an expected consequence of 5&nbsp;alpha‑reductase inhibition and did not result in any known adverse events.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>Dutasteride is administered orally in solution as a soft gelatin capsule. Following administration of a single 0.5&nbsp;mg dose, peak serum concentrations of dutasteride occur within 1 to3 hours.</p><p>Absolute bioavailability in man is approximately 60% relative to a 2 hour intravenous infusion. The bioavailability of dutasteride is not affected by food.</p><p>Distribution</p><p>Pharmacokinetic data following single and repeat oral doses show that dutasteride has a large volume of distribution (300 to 500&nbsp;L). Dutasteride is highly bound to plasma proteins (&gt;99.5%).</p><p>Following daily dosing, dutasteride serum concentrations achieve 65% of steady state concentration after 1 month and approximately 90% after 3 months.&nbsp; Steady state serum concentrations (C<sub>ss</sub>) of approximately 40 nanograms/mL are achieved after 6&nbsp;months of dosing 0.5 mg once a day.&nbsp; Similarly to serum, dutasteride concentrations in semen achieved steady state at 6&nbsp;months.&nbsp; After 52 weeks of therapy, semen dutasteride concentrations averaged 3.4 nanograms/mL (range 0.4 to 14 nanograms/mL). Dutasteride partitioning from serum into semen averaged 11.5%.</p><p>Biotransformation</p><p>In vitro, dutasteride is metabolised by the human cytochrome P450 isoenzyme CYP3A4 to two minor monohydroxylated metabolites, but it is not metabolised by CYP1A2, CY2A6, CYP2E1, CYP2C8, CYP2C9, CYP2C19, CYP2B6 or CYP2D6.</p><p>In human serum, following dosing to steady state, unchanged dutasteride, 3 major metabolites (4&#39;-hydroxydutasteride, 1,2-dihydrodutasteride and 6-hydroxydutasteride) and 2 minor metabolites (6,4&#39;-dihydroxydutasteride and 15-hydroxydutasteride), as assessed by mass spectrometric response, have been detected. The five human serum metabolites of dutasteride have been detected in rat serum, however the stereochemistry of the hydroxyl additions at the 6 and 15 positions in the human and rat metabolites is not known.</p><p>Elimination</p><p>Dutasteride is extensively metabolised. Following oral dosing of dutasteride 0.5&nbsp;mg/day to steady state in humans, 1.0% to 15.4% (mean of 5.4%) of the administered dose is excreted as dutasteride in the faeces. The remainder is excreted in the faeces as 4 major metabolites comprising 39%, 21%, 7%, and 7% each of drug-related material and 6&nbsp;minor metabolites (less than 5% each).</p><p>Only trace amounts of unchanged dutasteride (less than 0.1% of the dose)<strong> </strong>are detected in human urine.</p><p>At therapeutic concentrations, the terminal half-life of dutasteride is 3 to 5 weeks.</p><p>Serum concentrations remain detectable (greater than 0.1 ng/mL) for up to 4 to 6 months after discontinuation of treatment.</p><p>Linearity/non-linearity</p><p>Dutasteride pharmacokinetics can be described as first order absorption process and two parallel elimination pathways, one saturable (concentration‑dependent) and one non‑saturable (concentration‑independent).</p><p>At low serum concentrations (less than 3 nanograms/mL), dutasteride is cleared rapidly by both the concentration‑dependent and concentration‑independent elimination pathways. Single doses of 5&nbsp;mg or less showed evidence of rapid clearance and a short half-life of 3 to 9 days. &nbsp;</p><p>At serum concentrations, greater than 3&nbsp;nanograms/mL, dutasteride is cleared slowly (0.35 to 0.58&nbsp;L/h) primarily by linear, non-saturable elimination with terminal half-life of 3 to 5&nbsp;weeks. At therapeutic concentrations, following repeat dosing of 0.5&nbsp;mg/day, the slower clearance dominates and the total clearance is linear and concentration‑independent.</p><p>Elderly</p><p>Dutasteride pharmacokinetics and pharmacodynamics were evaluated in 36 healthy male subjects between the ages of 24 and 87 years following administration of a single 5&nbsp;mg dose of dutasteride. Exposure of dutasteride, represented by AUC and Cmax values, was not statistically different when comparing age groups. Half-life was not statistically different when comparing the 50 to -69 year old group to the greater than 70 years old group, which encompasses the age of most men with BPH. No differences in drug effect as measured by DHT reduction were observed between age groups. Results indicated that no dutasteride dose‑adjustment based on age is necessary.</p><p>Renal impairment</p><p>The effect of renal impairment on dutasteride pharmacokinetics has not been studied. However, less than 0.1% of a steady-state 0.5&nbsp;mg dose of dutasteride is recovered in human urine, so no adjustment in dosage is anticipated for patients with renal impairment.</p><p>Hepatic impairment</p><p>The effect on the pharmacokinetics of dutasteride in hepatic impairment has not been studied (<em>see Warnings and Precautions</em>).</p><p>Clinical Studies</p><p><strong><em>AVODART</em> monotherapy for BPH</strong></p><p>Dutasteride 0.5 mg/day or placebo was evaluated in 4325 male subjects with enlarged prostates (greater than 30&nbsp;cc) in three primary efficacy 2-year multicenter, placebo‑controlled, double-blind studies.</p><p>In men with BPH, <em>AVODART</em> treats and prevents disease progression by reducing the risk of&nbsp; both acute urinary retention (AUR) and the need for surgical intervention (SI) and by providing statistically significant improvement of lower urinary tract symptoms (LUTS), maximum urinary flow rate (Qmax) and prostate volume relative to placebo. These improvements in LUTS, Qmax and prostate volume were seen through to 24 months, and LUTS and Qmax continued to improved for a further 2&nbsp;years in open‑label extension studies.&nbsp; In addition, reductions in prostate volume were sustained for a further 2&nbsp;years in open‑label extension studies.</p><p><strong><em>AVODART</em></strong><strong> and tamsulosin combination therapy for BPH</strong></p><p><em>AVODART</em> 0.5mg/day, tamsulosin 0.4mg/day or the combination of <em>AVODART</em> 0.5&nbsp;mg plus tamsulosin 0.4&nbsp;mg was evaluated in 4844 male subjects with enlarged prostates (greater than or equal to 30cc) in a multicenter, double blind, parallel group study over 4 years. The primary efficacy endpoint at 2 years of treatment was the level of improvement from baseline in the international prostate symptom score (IPSS).</p><p>After 2 years of treatment, combination therapy showed a statistically significant adjusted mean improvement in symptom scores from baseline of -6.2 units.&nbsp; The adjusted mean improvements in symptom scores observed with the individual therapies were -4.9 units for <em>AVODART</em> and -4.3 units for tamsulosin.&nbsp; The adjusted mean improvement in flow rate from baseline was 2.4 ml/sec for the combination, 1.9 ml/sec for <em>AVODART</em> and 0.9 ml/sec for tamsulosin.&nbsp; The adjusted mean improvement in BPH Impact Index (BII) from baseline was -2.1 units for the combination, -1.7 for <em>AVODART</em> and -1.5 for tamsulosin.</p><p>The reduction in total prostate volume and transition zone volume after 2 years of treatment was statistically significant for combination therapy compared to tamsulosin monotherapy alone.</p><p>The primary efficacy endpoint at 4 years of treatment was time to first event of AUR or BPH-related surgery. After 4 years of treatment, combination therapy statistically significantly reduced the risk of AUR or BPH-related surgery (65.8% reduction in risk p&lt;0.001 [95% CI 54.7% to 74.1%]) compared to tamsulosin monotherapy.&nbsp; The incidence of AUR or BPH-related surgery by Year 4 was 4.2% for combination therapy and 11.9% for tamsulosin (p&lt;0.001). Compared to <em>AVODART</em> monotherapy, combination therapy reduced the risk of AUR or BPH-related surgery by 19.6%; the difference between treatment groups was not significant (p=0.18 [95% CI -10.9% to 41.7%]). &nbsp;The incidence of AUR or BPH-related surgery by Year 4 was 4.2% for combination therapy and 5.2% for <em>AVODART</em>.</p><p>Clinical progression was defined as a composite of worsening symptoms, (IPSS), and BPH-related events of AUR, incontinence, UTI, and renal insufficiency.&nbsp; Combination therapy was associated with a statistically significantly lower rate of clinical progression compared with tamsulosin (p&lt;0.001, 44.1% risk reduction [95 % CI: 33.6% to 53.0%]) after 4 years.&nbsp; The rates of clinical progression for combination therapy, tamsulosin, and <em>AVODART</em> were: 12.6%, 21.5%, and 17.8%, respectively.&nbsp;</p><p>The statistically significant adjusted mean improvement in symptom scores (IPSS) from baseline was maintained from year 2 to year 4.&nbsp; At 4 years, the adjusted mean improvements in symptom scores observed were -6.3 units for combination therapy, -5.3 units for <em>AVODART</em> monotherapy and -3.8 units for tamsulosin monotherapy.&nbsp;</p><p>After 4 years of treatment, the adjusted mean improvement in flow rate (Qmax) from baseline was 2.4 ml/sec for combination therapy, 2.0 ml/sec for <em>AVODART</em> monotherapy and 0.7 ml/sec for tamsulosin monotherapy.&nbsp; Compared with tamsulosin, the adjusted mean improvement from baseline in Qmax was statistically significantly greater with combination therapy at each 6‑month assessment from Month 6 to Month 48 (p&lt;0.001).&nbsp; Compared with <em>AVODART</em>, the adjusted mean improvement from baseline in Qmax was not statistically significantly different than with combination therapy (p=0.050 at Month 48).&nbsp;</p><p>Combination therapy was significantly superior (p&lt;0.001) to tamsulosin monotherapy and to <em>AVODART</em> monotherapy for the improvement in health outcome parameters BII and BPH-related Health Status (BHS) at 4 years.&nbsp; The adjusted mean improvement in BII from baseline was -2.2 units for the combination, -1.8 for <em>AVODART</em> and -1.2 for tamsulosin. The adjusted mean improvement in BHS from baseline was -1.5 units for the combination, -1.3 for <em>AVODART</em> and -1.1 for tamsulosin.</p><p>The reduction in total prostate volume and transition zone volume after 4 years of treatment was statistically significant for combination therapy compared to tamsulosin monotherapy alone.&nbsp;</p><p><strong>Cardiac failure </strong></p><p>In a 4-year comparison of <em>AVODART</em> coadministered with tamsulosin and dutasteride or tamsulosin monotherapy in men with BPH (the CombAT study), the incidence of the composite term cardiac failure in the combination group (14/1610, 0.9%) was higher than in either monotherapy group:&nbsp; <em>AVODART</em>, 4/1623 (0.2%) and tamsulosin, 10/1611, (0.6%).&nbsp; The relative risk estimate for time to first cardiac failure event was 3.57 [95% CI 1.17, 10.8] for combination treatment compared to <em>AVODART</em> monotherapy and 1.36 [95% CI 0.61, 3.07] compared to tamsulosin monotherapy.</p><p>In a 4-year chemoprevention, comparison study of placebo and <em>AVODART</em> in 8231 men aged 50 to 75, with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 ng/mL and 10.0 ng/mL (the REDUCE study) there was a higher incidence of the composite term cardiac failure in subjects taking <em>AVODART</em> (30/4105, 0.7%) versus placebo (16/4126, 0.4%) for a relative risk estimate for time to first cardiac failure event of 1.91 [95% CI 1.04, 3.50].&nbsp; In a post-hoc analysis of concomitant alpha blocker use, there was a higher incidence of the composite term cardiac failure in subjects taking <em>AVODART</em> and an alpha blocker concomitantly (12/1152, 1.0%), compared to subjects not taking <em>AVODART</em> and an alpha blocker concomitantly: <em>AVODART</em> and no alpha blocker (18/2953, 0.6%), placebo and an alpha blocker (1/1399, &lt;0.1%), placebo and no alpha blocker (15/2727, 0.6%). No causal relationship between <em>AVODART</em> (alone or in combination with an alpha blocker) and cardiac failure has been established (<em>see Warnings and Precautions</em>).</p><p><strong>Prostate cancer and high grade tumours</strong></p><p>In a 4-year comparison of placebo and <em>AVODART</em> in 8231 men aged 50 to 75, with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 ng/mL and 10.0 ng/mL (the REDUCE study), 6,706 subjects had prostate needle biopsy data available for analysis to determine Gleason Scores. There were 1517 subjects diagnosed with prostate cancer in the study. The majority of biopsy-detectable prostate cancers in both treatment groups were diagnosed as low grade (Gleason 5-6). There was no difference in the incidence of Gleason 7-10 cancers (p=0.81).</p><p>There was a higher incidence of Gleason 8-10 prostate cancers in the <em>AVODART</em> group (n=29, 0.9%) compared to the placebo group (n=19, 0.6%) (p=0.15).&nbsp; In Years 1-2, the number of subjects with Gleason 8-10 cancers was similar in the <em>AVODART</em> group (n=17, 0.5%) and the placebo group (n=18, 0.5%).&nbsp; In Years 3-4, more Gleason 8-10 cancers were diagnosed in the <em>AVODART</em> group (n=12, 0.5%) compared with the placebo group (n=1, &lt;0.1%) (p=0.0035).&nbsp; There are no data available on the effect of <em>AVODART</em> beyond 4 years in men at risk of prostate cancer.&nbsp; The percentage of subjects diagnosed with Gleason 8-10 cancers was consistent across study time periods (Years 1-2 and Years 3-4) in the <em>AVODART</em> group (0.5% in each time period), while in the placebo group, the percentage of subjects diagnosed with Gleason 8-10 cancers was lower during Years 3-4 than in Years 1-2 (&lt;0.1% versus 0.5%, respectively).&nbsp; In a 4 year BPH study (CombAT) where there were no protocol-mandated biopsies and all diagnoses of prostate cancer were based on for-cause biopsies, the rates of Gleason 8-10 cancer were (n=8, 0.5%) for <em>AVODART</em>, (n=11, 0.7%) for tamsulosin and (n=5, 0.3%) for combination therapy (<em>see Warnings and Precautions</em>).</p><p>The results of an epidemiological, population-based study (n=174,895) in community practice settings show that the use of 5-ARIs to treat BPH/LUTS is not associated with an increased risk of prostate cancer mortality (hazard ratio adjusted for competing risks: 0.85, 95% CI 0.72, 1.01) when compared with the use of alpha‑blockers. Similar results were reported in an epidemiological study (n=13,892) of men with prostate cancer in the UK (adjusted hazard ratio for prostate cancer mortality for 5-ARI users versus non-users: 0.86; 95% CI 0.69, 1.06). A prospective cohort study, the Health Professional&rsquo;s Follow-up Study (n=38,058), also found that 5-ARI use was not associated with fatal prostate cancer (adjusted HR: 0.99; 95% CI 0.58, 1.69).</p><p>&nbsp;</p><p><strong>Effects on prostate specific antigen (PSA) and prostate cancer detection</strong></p><p>In the REDUCE study, patients with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 ng/mL and 10.0 ng/mL, <em>AVODART</em> treatment caused a decrease in mean serum PSA by approximately 50% after six months of treatment with a large variability (standard deviation of 30%) among patients. The PSA suppression observed at six months was similar in men who did or who did not develop biopsy-detectable prostate cancer during the study. (<em>see Warnings and Precautions</em>).</p><p><strong>Incidence of breast cancer </strong></p><p>In BPH monotherapy clinical trials, providing 3374 patient years of exposure to <em>AVODART</em>, there were 2 cases of male breast cancer reported in <em>AVODART</em> -treated patients, one after 10 weeks and one after 11 months of treatment and 1 case in a patient who received placebo.&nbsp; In subsequent clinical trials in BPH and 8231 men aged 50 to 75, with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 ng/mL and 10.0 ng/mL providing 17489 patient years exposure to <em>AVODART</em> and 5027 patient years exposure to <em>AVODART</em> and tamsulosin combination there were no reported breast cancer cases in any of the treatment groups.</p><p>Two case control, epidemiological studies, one conducted in a US (n=339 breast cancer cases and n=6,780 controls) and the other in a UK (n=398 breast cancer cases and n=3,930 controls) healthcare database, showed no increase in the risk of developing male breast cancer with the use of 5‑ARIs (<em>see Warnings and Precautions</em>). Results from the first study did not identify a positive association for male breast cancer (relative risk for &sup3;&nbsp;1‑year of use before breast cancer diagnosis compared with &lt; 1‑year of use: 0.70: 95% CI 0.34, 1.45). In the second study, the estimated odds ratio for breast cancer associated with the use of 5-ARIs compared with non-use was 1.08: 95% CI 0.62, 1.87).</p><p>The relationship between long term use of dutasteride and male breast cancer has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>At exposures greatly in excess of those at the clinical dose, reversible, non‑specific CNS‑related effects were seen in rats (425-fold) and dogs (315-fold).</p><p>Other toxicity findings were consistent with the pharmacological activity of 5&nbsp;alpha‑reductase inhibition. In male rats and dogs, these included effects on accessory reproductive organs and, in male rats, a reversible decrease in fertility.&nbsp; This is considered to have no clinical relevance as there was no effect on sperm development, concentration or motility.&nbsp; Feminisation of the external genitalia was noted in male foetuses of female rats and rabbits orally dosed with dutasteride.&nbsp; However, intravenous administration of dutasteride to pregnant Rhesus monkeys during embryofoetal development at doses of up to 2010&nbsp;nanogram/animal/day did not produce adverse maternal or foetal toxicity.&nbsp; This dose represents a multiple of at least 186-fold (nanogram/kg basis) the potential maximum daily dose in a 50 kg woman, resulting from exposure to 5 mL semen (assuming 100% absorption) from a dutasteride-treated man.</p><p>Dutasteride was not genotoxic in a wide range of mutagenicity tests.</p><p>In a carcinogenicity study in rats, there was an increase in benign interstitial cell tumours in the testis at the high dose (158-fold clinical exposure).&nbsp; However, the endocrine mechanisms believed to be involved in the production of interstitial cell hyperplasia and adenomas in the rat are not relevant to humans.&nbsp; There were no clinically relevant effects on tumour profile in a carcinogenicity study in mice.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Capsule contents:</strong> monodiglycerides of caprylic/capric acid; butylated hydroxytoluene</p><p><strong>Capsule shell</strong>: gelatin; glycerol; titanium dioxide (E171, CI 77891); iron oxide yellow (E172, CI 77492).</p><p>Medium chain triglycerides and lecithin as capsule lubricants.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>store AVODART below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PVDC blisters.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dutasteride is absorbed through the skin, therefore women and children must avoid contact with leaking capsules <em>(see Warnings and Precautions and Pregnancy and Lactation</em>). If contact is made with leaking capsules the contact area should be washed immediately with soap and water.</p><p>Not all presentations are available in every country.</p><p>&nbsp;</p><p>&nbsp;</p><p>&copy; 2019 GSK group of companies, all rights reserved.</p><p><em>AVODART</em> is a trade mark owned by GSK group of companies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by: 
GlaxoSmithKline Pharmaceutical S.A.*, Poznan, Poland
Packed by: 
Glaxo Saudi Arabia Ltd.*, Jeddah – KSA
Marketing Authorisation Holder: 
Glaxo Saudi Arabia Ltd.* Jeddah, KSA
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia 
*member of the GlaxoSmithKline group of companies

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number: GDS20/IPI17
Date of issue: 11th April 2016

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>